| Literature DB >> 25281467 |
Jack Cuzick1, Mangesh A Thorat2, Gerald Andriole3, Otis W Brawley4, Powel H Brown5, Zoran Culig6, Rosalind A Eeles7, Leslie G Ford8, Freddie C Hamdy9, Lars Holmberg10, Dragan Ilic11, Timothy J Key12, Carlo La Vecchia13, Hans Lilja14, Michael Marberger15, Frank L Meyskens16, Lori M Minasian8, Chris Parker17, Howard L Parnes18, Sven Perner19, Harry Rittenhouse20, Jack Schalken21, Hans-Peter Schmid22, Bernd J Schmitz-Dräger23, Fritz H Schröder24, Arnulf Stenzl25, Bertrand Tombal26, Timothy J Wilt27, Alicja Wolk28.
Abstract
Prostate cancer is a common malignancy in men and the worldwide burden of this disease is rising. Lifestyle modifications such as smoking cessation, exercise, and weight control offer opportunities to reduce the risk of developing prostate cancer. Early detection of prostate cancer by prostate-specific antigen (PSA) screening is controversial, but changes in the PSA threshold, frequency of screening, and the use of other biomarkers have the potential to minimise the overdiagnosis associated with PSA screening. Several new biomarkers for individuals with raised PSA concentrations or those diagnosed with prostate cancer are likely to identify individuals who can be spared aggressive treatment. Several pharmacological agents such as 5α-reductase inhibitors and aspirin could prevent development of prostate cancer. In this Review, we discuss the present evidence and research questions regarding prevention, early detection of prostate cancer, and management of men either at high risk of prostate cancer or diagnosed with low-grade prostate cancer.Entities:
Mesh：
Substances：
Year: 2014 PMID： 25281467 PMCID： PMC4203149 DOI： 10.1016/S1470-2045(14)70211-6
Source DB: PubMed Journal: Lancet Oncol ISSN： 1470-2045 Impact factor: 41.316